March 20, 2014 | Israeli biotech startup Gamida Cell, which develops stem-cell based therapies, is reportedly in advanced acquisition talks at a company value of $600 million. The Times of Israel reports that the company has received a large buy-out offer from an international pharmaceutical company.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments